Strategic Review - Urgently Required, page-5

@Last of the Mohicans

I think this is a valid point made by @Smugtown

"If energies are being poured into data analytics, clinical trial, partnership agreement, best of breed device - and not on sales - because of the change of course of direction a few months ago - then i am ok with it if it expedites a multi national partnership. "

Is their energy focused on developing the product to be 'best of breed', hence the clinical trials which will then lead to formal recognition, more widespread subsidy offerings and potential partnering with majors ?

If they were to say 100% of their energy was focused on sales I would be concerned, but I would say it's 30% sales and still 70% development etc

At some point they have to remember it's a product and it needs to sell to keep the company afloat, but they obviously see value in what they are developing

If they have got a mention from the FDA and deliver positive clinical trial results, then it could increase acceptance and sales exponentially, especially with insurers/healthcare etc and the marketability of the product then